Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00911339
Other study ID # Atorvastatin-CD34+
Secondary ID
Status Terminated
Phase Phase 3
First received
Last updated
Start date January 2009
Est. completion date May 13, 2021

Study information

Verified date August 2021
Source IRCCS Policlinico S. Matteo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the extent of the mobilization of endothelial progenitor cells induced by low versus high dose atorvastatin after 4 weeks of treatment, in patients treated with anti-CD 34 antibodies coated stent.


Description:

Addition of statins to peripheral blood circulating mononuclear cells (PBMNCs) and to their CD 34+ subset cultures promotes endothelial progenitor cells (EPCs) proliferation, migration and survival according to a time and concentration-dependent effect. Data suggested that in patients with stable coronary artery disease atorvastatin 40 mg/day induced a 2 fold increase in the number of CD34+VEGFR2+ cells after 1 week of treatment and a 3 fold increase after 4 weeks; likewise, the number of EPCs colonies increased 1.5 times after 1 week and 3 times after 4 weeks. Data also suggested that the short term mobilizing effect of statins on EPCs may be transient and that medium-high doses long term statin treatment (> 1 month) may lead to a reduction in EPCs. Rather, a depletion of EPCs may not only be explained by exhausted mobilization but also by improved incorporation at sites of tissue hypoperfusion with potentially beneficial effects in therapeutic angiogenesis.In an interventional contest high concentrations of circulating EPCs may contribute to accelerate the reendothelialization process after stents implantation in coronary arteries. Considering the use of recent stents coated with anti-CD34 murine antibodies, the presence of high levels of PBMNCs expressing CD34 surface antigen may define the safety and efficacy levels of the procedure. Both the angiographic outcome and the clinical outcome seems to be better in patients with normal levels of EPCs than in patients with low levels. No data are available about the effects of different doses of statins on the biology of the PBMNCs and in particular about the timing of mobilization, duration of mobilization, the CD 34+ cell subset subpopulation mobilized and their gene expression balance in humans. No data are available about the effect of statins on clinical evolution in patients treated with PCI after the implantation of the stents coated by anti-CD34 murine antibodies.no specific data describing the effects of different doses of statins on the biology of the PBMNCs and in particular about the timing of mobilization, the duration of mobilization, the CD 34+ cell subset subpopulation mobilized and their gene expression balance in humans. No study has evaluated the effect of statins on clinical evolution in patients treated with PCI after the implantation of the new stents, coated by anti-CD34 murine antibodies. These data can contribute to better define the process of mobilization of endothelial progenitors induced by statins and to set up the best pharmacological strategy anti-CD34 coated stents deployment.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date May 13, 2021
Est. primary completion date May 13, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - age between 18 and 75 years - stable angina or silent ischemia - documented CAD - signed written informed consent Exclusion Criteria: - current or recent therapy (stop < 3 months) with statins - allergy to ASA or ticlopidine/clopidogrel - myocardial infarction (< 3 months) - recent significant trauma or surgical interventions (< 3 mesi) - significant renal or hepatic diseases - coagulative-hematological disorders - cancer - inflammatory diseases - myopathy - pregnancy (a pregnancy test will be performed in fertile women) - severe coronary calcification, or small vessels disease (< 2.5 mm), long lesions (> 20 mm), ostial lesions, bifurcation lesions requesting treatment of the collateral vessel, multi-vessel disease requiring PCI before the completion of the study

Study Design


Intervention

Drug:
Atorvastatin
Atorvastatin 10 mg associated with stent genous
Atorvastatin
Atorvastatin 80 mg associated with stent genous

Locations

Country Name City State
Italy Fondazione Irccs Policlinico San Matteo Pavia

Sponsors (1)

Lead Sponsor Collaborator
IRCCS Policlinico S. Matteo

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the extent of the mobilization of endothelial progenitor cells induced by low versus high dose atorvastatin after 4 weeks of treatment, in patients treated with anti-CD 34 antibodies coated stent. 7-28-90 days after enrollment
See also
  Status Clinical Trial Phase
Completed NCT01205425 - Computed Tomography Coronary Angiography Before Stent Implantation N/A
Completed NCT01243099 - Prospective Study to Assess DES Re-endothelization in BMS Restenosis and De-novo Lesions N/A
Completed NCT03312855 - Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept Phase 2
Completed NCT00642811 - A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders Phase 2
Recruiting NCT03089450 - To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent N/A
Completed NCT01523392 - A Pharmacodynamic Study With Ticagrelor in African American Patients Phase 4
Completed NCT01209637 - Impact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CAD N/A
Active, not recruiting NCT04434365 - Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease Phase 1/Phase 2
Completed NCT00510588 - Chronic Inflammatory Activation in Fat Tissue: an Atherogenic Factor in Stable Coronary Artery Disease N/A
Completed NCT03384966 - A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease Phase 2
Active, not recruiting NCT01609465 - Prognostic Models for People With Stable Coronary Artery Disease N/A
Completed NCT00984802 - Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy Phase 2
Completed NCT03782688 - Precise Percutaneous Coronary Intervention Plan (P3) Study
Completed NCT02580851 - Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention N/A
Recruiting NCT03313752 - Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity Phase 3
Completed NCT01184300 - ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation Phase 2/Phase 3
Completed NCT01523366 - A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Phase 4
Completed NCT01118325 - An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease Phase 2
Recruiting NCT06123728 - MCG is Clinically Applied to Evaluate Myocardial Ischemic Function in Patients With Stable Coronary Artery Disease